AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 ...

HER3-DXd demonstrated activity in a phase 3 trial of patients with previously treated, EGFR-mutant NSCLC, but the BLA for HER3-DXd has been withdrawn.

DelveInsight's, “Gastrointestinal Stromal Tumors Pipeline Insight 2025” report provides comprehensive insights about 25+ ...

In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in ...

Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market in the UK, through a ground-breaking collaboration with AstraZeneca.

During a live event, Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and ...

Following approval in the US, AstraZeneca is required to pay $45 million to Daiichi Sankyo as a milestone payment for the locally advanced or metastatic EGFR-mutated NSCLC indication.

Only those projects for which Daiichi Sankyo will continue R&D will be transferred to the R&D division. For other assets, we are currently looking at other opportunities including out-licensing.

View the latest Daiichi Sankyo Co. Ltd. (DSKYF) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Daiichi Sankyo and MSD's partnership, which began in October 2023, encompasses the co-development and commercialisation of patritumab deruxtecan (HER3-DXd), raludotatug deruxtecan (R-DXd), and I-DXd.

Review the current valuation for Daiichi Sankyo Co Ltd (4568:XTKS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.